Mast Cell Activation Syndrome and Pancreatic Damage

Understanding MCAS and Its Systemic Effects

The American Academy of Allergy, Asthma, and Immunology defines MCAS as a primary clinical condition characterized by spontaneous episodic signs and symptoms affecting at least 2 organ systems resulting from secreted mast cell mediators 1
Mast cells release inflammatory mediators including histamine, prostaglandin D2, and leukotriene C4, which can affect multiple organ systems, according to the Journal of Allergy and Clinical Immunology 1, 2
Symptoms typically occur in multiple body systems, including gastrointestinal, cardiovascular, respiratory, and dermatologic systems, as reported by the Journal of Allergy and Clinical Immunology 1, 3

Mast cells are present in connective tissue throughout the body, including around the pancreas, as noted in Clinical Gastroenterology and Hepatology 4
When mast cells degranulate, they release proinflammatory molecules that could theoretically affect surrounding tissues, according to Clinical Gastroenterology and Hepatology 4
These inflammatory mediators can cause local tissue inflammation, which could potentially affect pancreatic function if occurring near or within pancreatic tissue, as suggested by the Journal of Allergy and Clinical Immunology and Clinical Gastroenterology and Hepatology 1, 2

MCAS diagnosis requires recurrent episodes affecting at least 2 organ systems, documented increase in mast cell mediators during symptomatic episodes, and response to medications targeting mast cell mediators, as recommended by the Journal of Allergy and Clinical Immunology and Clinical Gastroenterology and Hepatology 1, 2, 5
Serum tryptase should be measured at baseline and during symptomatic episodes, with an increase of 20% above baseline plus 2 ng/mL considered significant, according to Clinical Gastroenterology and Hepatology 5

Treatment of MCAS focuses on controlling mast cell activation with H1 and H2 histamine receptor antagonists, leukotriene receptor antagonists, and COX inhibitors, as reported by the Journal of Allergy and Clinical Immunology 6
Dietary interventions, including low-histamine diets, may be considered for improving GI symptoms but should be implemented with appropriate nutritional counseling, as suggested by Clinical Gastroenterology and Hepatology 4

The American Gastroenterological Association notes that mast cell degranulation releases histamine and other inflammatory mediators, directly acting on intestinal mucous glands to cause excessive mucus secretion, leading to a shiny, reflective coating on stool in patients with mast cell disorders 7
Mast cell mediators can stimulate mucous glands to hypersecrete, creating a shiny, reflective coating on stool, and act on intestinal smooth muscles to cause altered motility and contractions, triggering sensory nerve endings leading to abdominal pain 7
The shiny or metallic appearance of stool in mast cell disorders reflects light off the excessive mucus coating rather than undigested fat, which would appear greasy and float 7
Patients with mast cell activation syndrome commonly present with GI symptoms, including abdominal cramping and pain, which occur in approximately 71% of patients with confirmed alpha-gal syndrome, a condition mediated by mast cells 7
Diarrhea with mucus is a frequent manifestation of mast cell disorders, and nausea and vomiting affect about 22% of patients, with symptoms sometimes occurring without skin, respiratory, or circulatory findings 7, 8

The American College of Gastroenterology recommends measuring serum tryptase levels, including baseline tryptase when asymptomatic, and acute tryptase 1-4 hours after symptom onset, to confirm mast cell involvement as the cause of stool changes, with an increase of 20% above baseline plus 2 ng/mL being diagnostic for mast cell activation 8

The European Society for Clinical Nutrition and Metabolism suggests that first-line therapy for GI symptoms from mast cell activation includes H1 antihistamines as initial therapy, with H2 antihistamines added if symptoms persist, and oral cromolyn sodium as a mast cell stabilizer particularly effective for GI manifestations 9